Glenmark Pharmaceuticals share price rallies 15% as firm launches COVID-19 drug Favipiravir

By: |
June 22, 2020 10:20 AM

Glenmark Pharma stock has gained 180 per cent in less than three months from its 52-week low of Rs 168 apiece, taking the market capitalisation of the company to Rs 13,274.60 crore

Glenmark PharmaceuticalsGlenmark Pharma informed that the drug will be available as a prescription-based medication for Rs 103 per tablet

Glenmark Pharmaceuticals share price rallied 15 per cent to Rs 470.45 apiece on BSE after the company on Saturday after the company announced the launch of antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients. Glenmark Pharma stock has gained 180 per cent in less than three months from its 52-week low of Rs 168 apiece, taking the market capitalisation of the company to Rs 13,274.60 crore. The stock is just 9 per cent away from its all-time of Rs 517.70 touched in June last year. “The company has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19,” Glenmark Pharma said in a statement.

Glenmark Pharma informed that the drug will be available as a prescription-based medication for Rs 103 per tablet, with recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14. “Favipiravir can be used in COVID-19 patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID 19 symptoms,” company said. “This approval comes at a time when cases in India are spiralling like never before, putting tremendous pressure on our healthcare system. We hope the availability of an effective treatment such as FabiFlu® will considerably help assuage this pressure and offer patients in India a much needed and timely therapy option,” said Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd.

COVID-19 patients show high viral load at the time of symptom onset suggests treating with a combination of antiviral drugs- highly effective and minimize the emergence of resistance, Glenmark said in a press brief. “In line with this strategy, Glenmark proposes to combine two anti-viral drugs Favipiravir (An approved drug for novel flu pandemics) with Umifenovir (An approved drug for Influenza) – safety well established. Both drugs acting on different mechanisms the combined use of Favipiravir and Umifenovir offers a comprehensive antiviral cover on pre-entry and post-entry life-cycle of SARS-CoV-2 virus,” it added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Gold prices off 10% from record high; prices may inch near Rs 52,000 per 10 gm by Nov-end
2L&T share price runs like bullet train, after firm emerges lowest bidder for Mumbai-Ahmedabad track
3Asian shares track Wall Street fall as coronavirus aid hopes fade